Showing 1 - 10 of 8,811
Non-melanoma skin cancer (NMSC) and actinic keratosis are becoming an increasingly important healthcare problem. There are approximately 1 million cases of NMSC in the US each year, primarily basal cell carcinomas, and the incidence is increasing. Although NMSC is significant in terms of both...
Persistent link: https://www.econbiz.de/10005449242
Although interferon alpha (IFN) has been approved since 1995 in the US as adjuvant therapy for high-risk melanoma patients, its cost effectiveness and economic value have only been recently addressed. There are very few papers that address the overall cost and cost components of treating...
Persistent link: https://www.econbiz.de/10005449264
Objective: Cancer-related anaemia is associated with fatigue that adversely affects patients' everyday functioning and wellbeing. We explore the impact of fatigue on patient productivity and caregiver burden. Methods: The analyses are based on data from a randomised, open-label,...
Persistent link: https://www.econbiz.de/10005404812
As healthcare expenditures continue to rise, financial pressures have resulted in a desire for countries to shift resources away from_ traditional areas of spending. The consequent devolution and reform have resulted in increased care being provided and received within homes and communities, and...
Persistent link: https://www.econbiz.de/10005404864
Background:Background: When guidelines for health economic evaluations prescribe that a societal perspective should be adopted, productivity costs should be included. However, previous research suggests that, in practice, productivity costs are often neglected. This may considerably bias the...
Persistent link: https://www.econbiz.de/10011005068
increased morbidity and mortality on a global scale. Because of the widespread and debilitating nature of the disease, annual …
Persistent link: https://www.econbiz.de/10004990326
Many employers in the US are investing in new programmes to improve the quality of medical care and simultaneously shifting more of the healthcare costs to their employees without understanding the implications on the amount and type of care their employees will receive. These seemingly...
Persistent link: https://www.econbiz.de/10005590264
Which costs and benefits to consider in economic evaluations of healthcare interventions remains an area of much controversy. Unrelated medical costs in life-years gained is an important cost category that is normally ignored in economic evaluations, irrespective of the perspective chosen for...
Persistent link: https://www.econbiz.de/10005590343
Many low- and middle-income countries continue to search for better ways of financing their health systems. Common to many of these systems are problems of inadequate resource mobilisation, as well as inefficient and inequitable use of existing resources. The poor and other vulnerable groups who...
Persistent link: https://www.econbiz.de/10005448953
In economic evaluation of healthcare programmes both QOL and productivity of patients are aspects to be studied. Normally, the former is part of the measurement of the effectiveness of the programme and the latter is part of the measurement of its costs. In this paper we highlight the...
Persistent link: https://www.econbiz.de/10005243161